BioSpace News Archive

Hippocampus Atrophy and Cortical Thinning Correlate with Cognitive Decline and Show Promise as Biomarkers in Alzheimer’s Treatment and Prevention Clinical Trials

MiCAN Technologies, a research service provider based in Kyoto Japan, revealed that its human myeloid lineage cells[1] have been used to conduct research on the coronavirus SARS-CoV-2, which is responsible for the COVID-19 infectious disease.

Returning for its seventh season, Walgreens Flu Index® encourages consumers to take protective health measures and avoid a ‘twindemic’ as COVID-19 cases continue to rise

Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the appointment of Michael Heffernan to its board of directors.

POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, today announced the appointment of Jonathan Ross Goodman, Gerry Hogue and Peggy Gilmour to its Board of Directors.

Mesa Biotech, developers of an affordable, easy to use, handheld testing platform for infectious disease diagnosis, today announced it has received 510(k) clearance and Clinical Laboratory Improvements Amendments (CLIA) waiver from the US Food and Drug Administration (FDA) for its Accula™ Strep A test.

Micronoma, the first cancer detection biotech company that uses signals from the tumor-related microbiome to diagnose cancer at an early stage with minimally-invasive liquid biopsy technology, today announced the formation of its scientific advisory board (SAB).

Supported by Hillhouse Capital’s proven brand and deep network in Asia, Overland will execute on mission to form strategic alliances with innovative biotech companies to jointly develop and commercialize novel therapeutic programs

REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced interim data from Cohorts 1 and 2 of the ongoing Phase I/II trial of RGX-121 for the treatment of patients up to 5 years old diagnosed with Mucopolysaccharidosis Type II (MPS II).

ZielBio, Inc., an early-stage biotechnology company discovering new treatments for cancer and other serious diseases through its innovative drug discovery platform, has appointed industry veteran Dieter Weinand as the company’s new Executive Chair.